Our Blog

 

Association of Statin Adherence with Mortality in Patients with Atherosclerotic Cardiovascular Disease

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Feb 24, 2019 | 0 Comments

Association of Statin Adherence with Mortality in Patients with Atherosclerotic Cardiovascular Disease By Heather Nelson Cortes, PhD and Kevin C Maki, PhD   There is little doubt of the role that statins play in the reduction of mortality risk, mainly attributable to a benefit on death from cardiovascular causes.  A meta-analysis of statin clinical trials

Read More

More Evidence that Low-density Lipoprotein Cholesterol and Triglyceride-lowering Genetic Variants Reduce Risk of Coronary Heart Disease

By Kevin C Maki PhD and Mary R Dicklin PhD | Feb 10, 2019 | 0 Comments

More Evidence that Low-density Lipoprotein Cholesterol and Triglyceride-lowering Genetic Variants Reduce Risk of Coronary Heart Disease By Kevin C Maki, PhD and Mary R Dicklin, PhD   The total cholesterol concentration in circulation is comprised of cholesterol carried by three main types of lipoproteins:  low-density lipoproteins (LDL), very-low-density lipoproteins (VLDL) and high-density lipoproteins (HDL).  VLDL

Read More

Viscous Fiber Supplements in Diabetes Control: Results from a Systematic Review and Meta-analysis of Randomized Controlled Trials

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Feb 9, 2019 | 0 Comments

Viscous Fiber Supplements in Diabetes Control: Results from a Systematic Review and Meta-analysis of Randomized Controlled Trials By Heather Nelson Cortes, PhD and Kevin C Maki, PhD According to the recent 2019 American Diabetes Association (ADA) Standards of Medical Care in Diabetes, people with diabetes should increase their intake of viscous fiber from sources such

Read More

Potential Cognitive Benefits of Intensive Blood Pressure Lowering

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Feb 5, 2019 | 0 Comments

Potential Cognitive Benefits of Intensive Blood Pressure Lowering By Heather Nelson Cortes, PhD and Kevin C Maki, PhD Currently there are no well-established clinical interventions for the prevention of mild cognitive impairment (MCI) or dementia.  Alzheimer’s disease and dementia are expected to affect 115 million people worldwide by the year 20501.  More than 75% of

Read More

Comparing the Effectiveness of Second-line Antidiabetic Medications on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

By Mary R Dicklin PhD Kevin Maki PhD | Dec 31, 2018 | 0 Comments

Comparing the Effectiveness of Second-line Antidiabetic Medications on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus By Mary R Dicklin, PhD and Kevin C Maki, PhD, CLS, FNLA   Cardiovascular disease is the leading cause of morbidity and mortality among patients with type 2 diabetes (T2D).1  Metformin is widely recommended as first-line therapy, but

Read More

2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Dec 3, 2018 | 0 Comments

2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines 2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines  By Heather Nelson Cortes, PhD, Mary R Dicklin, PhD and Kevin C Maki, PhD   The American College of Cardiology (ACC) and the American Heart Association (AHA) recently released their 2018 Guideline on

Read More

Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Nov 30, 2018 | 0 Comments

Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL  By Heather Nelson Cortes, PhD and Kevin C Maki, PhD  Dapagliflozin and Cardiovascular Events in the DECLARE-TIMI 58 Trial The Dapagliflozin Effect on Cardiovascular Events—Thrombolysis

Read More

More Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions 2

By Kevin C Maki PhD and Mary R Dicklin PhD | Nov 29, 2018 | 0 Comments

More Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions – Less Pessimism Called for When Interpreting the Results from VITAL Regarding Cardiovascular Benefits with Omega-3   By Kevin C Maki, PhD and Mary R Dicklin, PhD  The primary results from the Vitamin D and Omega-3 Trial (VITAL) were

Read More

Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions

By Kevin C Maki PhD and Mary R Dicklin PhD | Nov 27, 2018 | 1 Comment

Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions – REDUCE-IT – a Landmark Cardiovascular Outcomes Study of an Omega-3 Fatty Acid   By Kevin C Maki, PhD and Mary R Dicklin, PhD  The primary results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial

Read More

Mechanisms Responsible for the Benefit on Cardiovascular Risk in the REDUCE-IT Trial

By Kevin Maki PhD | Oct 12, 2018 | 0 Comments

Mechanisms Responsible for the Benefit on Cardiovascular Risk in the REDUCE-IT Trial By Kevin C Maki, PhD   Recently, we learned of the impressive topline results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial (REDUCE-IT), which showed that Vascepa® (icosapent ethyl or EPA ethyl esters) lowered major adverse cardiovascular events

Read More